Interaction between CYP1A2-T2467DELT polymorphism and smoking in adenocarcinoma and squamous cell carcinoma of the lung

Lung Cancer

Volumn 57, Issue 3, 2007, Pages 266-272

  Pavanello, Sofia ^a   B'chir, Fatma ^b   Pulliero, Alessandra ^a   Saguem, Saâd ^b   Ben Fraj, Radhia ^b   El Aziz Hayouni, Abed ^c   Clonfero, Erminio ^a   Mastrangelo, Giuseppe ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b Faculty of Medicine   (Tunisia)

^c FARHAT HACHED HOSPITAL   (Tunisia)

Author keywords

Adenocarcinoma of the lung; Carcinogens' activation; Case only study; CYP1A2 T2467delT genotype; Genetic susceptibility; Smoke; Squamous cell carcinoma of the lung

Indexed keywords

CYTOCHROME P450 1A2; TOBACCO SMOKE;

ADULT; AGED; ARTICLE; CANCER SUSCEPTIBILITY; CELL INTERACTION; CONTROLLED STUDY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HISTOPATHOLOGY; HUMAN; LIFESTYLE; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE; SQUAMOUS CELL CARCINOMA; STATISTICAL SIGNIFICANCE; TOBACCO;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CYTOCHROME P-450 CYP1A2; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK; SMOKING; TUNISIA;

EID: 34548023712     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.04.004     Document Type: Article

References (48)

1. Shou M., Gonzalez F.J., and Gelboin H.V. Stereoselective epoxidation and hydration at the k-region of polycyclic aromatic hydrocarbons by cDNA-expressed cytochromes P450 1A1, 1A2, and Epoxide Hydrolase. Biochemistry 35 (1996) 15807-15813
2. Boobis A.R., Lynch A.M., Murray S., de la Torre R., Solans A., Farre M., et al. CYP1A2-catalyzed conversion of dietary heterocyclic amines to their proximate carcinogens is their major route of metabolism in humans. Cancer Res 54 (1994) 89-94
3. Butler M.A., Iwasaki M., Guengerich F.P., and Kadlubar F.F. Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci USA 86 (1989) 7696-7700
4. IARC. Working Group on the Evaluation of Carcinogenic Risks to Humans. Tobacco smoke and involuntary smoking vol. 83 (2004), IARC Scientific Publications, IARC, Lyon p. 1-438
5. Bartsch H., Nair U., Risch A., Rojas M., Wikman H., and Alexandrov K. Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. Cancer Epidemiol Biomark Prev 9 (2000) 3-28
6. Sesardic D., Boobis A.R., Edwards R.J., and Davies D.S. A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the odeethylation of phenacetin and is inducible by cigarette smoking. Br J Clin Pharmacol 26 (1988) 363-372
7. Chung W.G., Kang J.H., Park C.S., Cho M.H., and Cha Y.N. Effect of age and smoking on in vivo CYP1A2, flavin-containing monooxygenase, and xanthine oxidase activities in Koreans: determination by caffeine metabolism. Clin Pharmacol Ther 67 (2000) 258-266
8. Nordmark A., Lundgren S., Cnattingius S., and Rane A. Dietary caffeine as a probe agent for assessment of cytochrome P4501A2 activity in random urine samples. Br J Clin Pharmacol 47 (1999) 397-402
9. Landi M.T., Sinha R., Lang N.P., and Kadlubar F.F. Human cytochrome P4501A2. In: Vineis P., Malats N., Lang M., d'Errico A., Caporaso N., Cuzick J., and Boffetta P. (Eds). Metabolic polymorphisms and susceptibility to cancer 148 (1999), IARC Scientific Publications, IARC, Lyon p. 173-95 [Chapter 16]
10. Butler M.A., Lang N.P., Young J.F., Caporaso N.E., Vineis P., Hayes R.B., et al. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 2 (1992) 116-127
11. Pavanello S., Pulliero A., Lupi S., Gregorio P., and Clonfero E. Influence of the genetic polymorphism in the 5′-noncoding region of the CYP1A2 gene on CYP1A2 phenotype and urinary mutagenicity in smokers. Mutat Res 587 (2005) 59-66
12. Charloux E., Quoix N., Wolkove D., Small G., and Pauli Kreisman H. The increasing incidence of lung adenocarcinoma: reality or artefact? A review of the epidemiology of lung adenocarcinoma. Int J Epidemiol 26 (1997) 14-23
13. Devesa S.S., Shaw G.L., and Blot W.J. Changing patterns of lung cancer incidence by histological type. Cancer Epidemiol Biomark Prev 1 (1991) 29-34
14. Wingo P.A., Ries L.A., Giovino G.A., Miller D.S., Rosenberg H.M., Shopland D.R., et al. Annual report to the nation on the status of cancer, 1973-1996, with a special section on lung cancer and tobacco smoking. J Natl Cancer Inst 91 (1999) 675-690
15. Hecht S.S. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 91 (1999) 1194-2110
16. Hoffmann D., and Hoffmann I. The changing cigarette, 1950-1995. J Toxicol Environ Health 50 (1997) 307-364
17. Brownson R.C., Alavanja M.C., Caporaso N., Simoes E.J., and Chang J.C. Epidemiology and prevention of lung cancer in nonsmokers. Epidemiol Rev 20 (1998) 218-236
18. Ferlay J., Bray F., Pisani P., and Parkin D.M. Globocan 2000: cancer incidence, mortality and prevalence worldwide, version 1.0. (2001), IARC Press, IARC Cancer Base No 5, Lyon
19. Fakhfakh R., Hsairi M., Maalej M., Achour N., and Nacef T. Tobacco use in tunisia: behaviour and awareness. Bull World Health Org 80 (2002) 350-356
20. Bonner M.R., Bennet W.P., Xiong W., Lan Q., Brownson R.C., Harris C.C., et al. Radon, secondhand smoke, glutathione-S-transferase M1 and lung cancer among women. Int J Cancer 119 (2006) 1462-1467
21. Mechanic L.E., Marrogi A.J., Welsh J.A., Bowman E.D., Khan M.A., Enewold L., et al. Polymorphisms in XPD and TP53 and mutation in human lung cancer. Carcinogenesis 26 (2005) 597-604
22. Skarke C., Kirchhof A., Geisslinger G., and Lotsch J. Rapid genotyping for relevant CYP1A2 alleles by pyrosequencing. Eur J Clin Pharmacol 61 (2005) 887-892
23. Hamdy S.I., Hiratsuka M., Narahara K., Endo N., El-Enany M., Moursi N., et al. Genotyping of four genetic polymorphisms in the CYP1A2 gene in the Egyptian population. Br J Clin Pharmacol 55 (2003) 321-324
24. Chida M., Yokoi T., Fukui T., Kinoshita M., Yokota J., and Kamataki T. Detection of three genetic polymorphisms in the 5′-flanking region and intron 1 of human CYP1A2 in the Japanese population. Jpn J Cancer Res 90 (1999) 899-902
25. Seow A., Zhao B., Lee E.J., Poh W.T., Teh M., Eng P., et al. Cytochrome P4501A2 (CYP1A2) activity and lung cancer risk: a preliminary study among Chinese women in Singapore. Carcinogenesis 22 (2001) 673-677
26. Chiou H.L., Wu M.F., Chien W.P., Cheng Y.W., Wong R.H., Chen C.Y., et al. NAT2 fast acetylator genotype is associated with an increased risk of lung cancer among never-smoking women in Taiwan. Cancer Lett 223 (2005) 93-101
27. Mace K., Bowman E.D., Vautravers P., Shields P.G., Harris C.C., and Pfeifer A.M. Characterisation of xenobiotic-metabolising enzyme expression in human bronchial mucosa and peripheral lung tissues. Eur J Cancer 34 (1998) 914-920
28. Wei R.J., Cacavale J.J., Kehoe P.E., Thomas, and Iba M.M. CYP1A2 is expressed along with CYP1A1 in the human lung. Cancer Lett 164 (2001) 25-32
29. Bernauer U., Heinrich-Hirsch B., Tonnies M., Peter-Matthias W., and Gundert-Remy U. Characterisation of the xenobiotic-metabolizing cytochrome P450 expression pattern in human lung tissue by immunochemical and activity determination. Toxicol Lett 164 (2006) 278-288
30. Sinues B., Saenz M.A., Lanuza J., Bernal M.L., Fanlo A., Juste J.L., et al. Five caffeine metabolite ratios to measure tobacco-induced CYP1A2 activity and their relationships with urinary mutagenicity and urine flow. Cancer Epidemiol Biomark Prev 8 (1999) 159-166
31. Murray S., Lake B.G., Gray S., Edwards A.J., Springall C., Bowey E.A., et al. Effect of cruciferous vegetable consumption on heterocyclic aromatic amine metabolism in man. Carcinogenesis 22 (2001) 1413-1420
32. Pavanello S., Simioli P., Lupi S., Gregorio P., and Clonfero E. Exposure levels and cytochrome P450 1A2 activity, but not N-acetyltransferase, glutathione S-transferase (GST) M1 and T1, influence urinary mutagen excretion in smokers. Cancer Epidemiol Biomark Prev 11 (2002) 998-1003
33. Pavanello S., Simioli P., Mastrangelo G., Lupi S., Gabbani G., Gregorio P., et al. Role of metabolic polymorphisms NAT2 and CYP1 A2 on urinary mutagenicity after a pan-fried hamburger meal. Food Chem Toxicol 40 (2002) 1139-1144
34. Bartsch H., Caporaso N., Coda M., Kadlubar F., Malaveille C., Skipper P., et al. Carcinogen hemoglobin adducts, urinary mutagenicity, and metabolic phenotype in active and passive cigarette smokers. J Natl Cancer Inst 82 (1990) 1826-1831
35. Landi M.T., Zocchetti C., Bernucci I., Kadlubar F.F., Tannenbaum S., Skipper P., et al. Cytochrome P4501A2: enzyme induction and genetic control in determining 4-aminobiphenyl-hemoglobin adduct levels. Cancer Epidemiol Biomark Prev 5 (1996) 693-698
36. Nakachi K., Imai K., Hayashi S., Watanabe J., and Kawajiri K. Genetic susceptibility to squamous cell carcinoma of the lung in relation to cigarette smoking dose. Cancer Res 51 (1991) 5177-5180
37. Nakachi K., Imai K., Hayashi S., and Kawajiri K. Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. Cancer Res 53 (1993) 2994-2999
38. Hayashi S., Watanabe J., and Kawajiri K. High susceptibility to lung cancer analyzed in terms of combined genotypes of CYP1A1 and Mu-class glutathione S-transferase genes. Jpn J Cancer Res 83 825 (1992) 866-870
39. Le Marchand L., Sivaraman L., Pierce A., Seifried A., Lum A., Wilkens L.R., et al. Association of CYP1A1, GSTM1, and CYP2E1 polymorphisms with lung cancer suggest cell type specificities to tobacco carcinogens. Cancer Res 58 (1998) 4858-4863
40. Deutsch-Wenzel R., Brune H., Grimmer G., Dettbarn G., and Misfeld J. Experimental studies in rat lungs on the carcinogenicity and dose-response relationships of eight frequently occurring environmental polycyclic aromatic hydrocarbons. J Natl Cancer Inst 71 (1983) 539-544
41. Greenblatt M.S., Bennett W.P., Hollstein M., and Harris C.C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54 (1994) 4855-4878
42. Takeshima Y., Seyama T., Bennett W.P., Akiyama M., Tokuoka S., Inai K., et al. p53 mutations in lung cancers from non-smoking atomic-bomb survivors. Lancet 342 (1993) 1520-1521
43. Denissenko M.F., Pao A., Tang M.S., and Pfeifer G.P. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in p53. Science 274 (1996) 430-432
44. Pavanello S., Simioli P., Carrieri M., Gregorio P., and Clonfero E. Tobacco-smoke exposure indicators and urinary mutagenicity. Mutat Res 521 (2002) 1-9
45. Talaska G., Ginsburg D., LaDow K., Puga A., Dalton T., and Warshawsky D. Impact of Cyp1a2 or Ahr gene knockout in mice: implications for biomonitoring studies. Toxicol Lett 162 (2006) 246-249
46. Alexandrie A.K., Nyberg F., Warholm M., and Rannug A. Influence of CYP1A1, GSTM1, GSTT1, and NQO1 genotypes and cumulative smoking dose on lung cancer risk in a Swedish population. Cancer Epidemiol Biomark Prev 13 (2004) 908-914
47. Song N., Tan W., Xing D., and Lin D. CYP 1A1 polymorphism and risk of lung cancer in relation to tobacco smoking: a case-control study in China. Carcinogenesis 22 (2001) 11-16
48. Vineis P. The relationship between polymorphisms of xenobiotic metabolizing enzymes and susceptibility to cancer. Toxicology 181-182 (2002) 457-462